Hepatoprotective Ergostane and Lanostane Derivatives from Mushrooms for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease: A Review

Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the chronic liver diseases. In the discovery of novel leads for the treatment of MAFLD, oxysterols and bile acids have received considerable attention. Ergostane and lanostane derivatives share structural similarities with oxysterols and bile acids and many mushroom derived ergostane and lanostane derivatives were shown to have anti-MAFLD potential. This review focuses on mushroom derived ergostanes and lanostanes with anti-MAFLD effect. Five ergostane and fifteen lanostane derivatives were reported from mushrooms with anti-MAFLD effect; interestingly most of them were from polypore mushrooms. Though deeper studies are needed to establish the efficacy and long-term safety of mushroom derived ergostane and lanostane derivatives, the available evidence supports the potential of mushroom derived tetracyclic triterpenoids in alleviating MAFLD; screening this chemo diversity might yield some useful clues for the management of MAFLD.